文献速递乳腺癌

基于人工智能的肿瘤浸润淋巴细胞定量在三阴性乳腺癌中的独立验证研究

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
PubMed 文献 · Lancet Oncol · 2026-01-01

CATALINA是一项独立外部验证研究,基于七项随机对照试验汇总的前瞻性长期结局数据,评估两种AI流程生成的cTIL评分与病理学家sTIL评分的预后效能。在1759例患者中,cTIL与sTIL呈中等相关,两者均独立改善5年生存预后判别,但cTIL在结合临床病理变量与sTIL后未提供增量预后价值。

要点

  • sTIL与cTIL均独立改善5年iDFS、DDFS和OS的判别。
  • cTIL在结合临床病理变量与sTIL后无增量预后价值。

核心结论

  • 两种cTIL模型在完全未再训练或修改的独立验证中提供了统计学显著的预后信息,并较单纯临床病理变量改善了风险判别。
  • cTIL评分在结合临床病理变量与sTIL评分后未维持统计学显著的预后关联。
  • cTIL评分未在临床病理变量联合sTIL模型基础上进一步显著改善5年AUC。
  • 研究支持将cTIL作为可重复的预后生物标志物,尤其适用于常规或广泛病理评估不可及的场景。

研究设计与样本

  • CATALINA为独立外部验证研究,使用七项多中心随机临床试验前瞻性收集的长期临床结局数据汇总。
  • 通过盲法独立部署锁定模型,评估两种此前已验证的AI流程生成的五种cTIL评分。
  • cTIL与病理学家sTIL均值在220张数字化H&E全切片图像中相关分析,该队列为早期三阴性或HER2阳性乳腺癌且此前经培训病理学家评分。
  • 预后效能评估在另一独立队列中进行,该队列为七项前瞻性随机辅助试验汇总的早期三阴性乳腺癌患者。
  • 采用多变量Cox回归调整临床病理因素和研究异质性,评估cTIL与sTIL与iDFS、DDFS和OS的关联,5年判别用时间依赖AUC估计。

主要发现

  • 共汇总1759例患者个体数据,其中1356例具备完整临床病理数据、病理学家sTIL评分和cTIL评分。
  • 在调整临床病理变量和sTIL评分的模型中,cTIL评分未维持统计学显著的预后关联;sTIL和cTIL均较单纯临床病理变量改善5年AUC,但cTIL在联合临床病理变量与sTIL后未显著进一步改善AUC。

临床怎么用

  • cTIL评分可作为可重复的预后生物标志物用于早期三阴性乳腺癌风险分层。
  • 在常规或广泛病理学家TIL评估不可及的场景,可考虑应用cTIL评分辅助预后判断。
  • cTIL不应替代sTIL联合临床病理变量的综合预后评估,因其未显示增量预后价值。

局限性

  • cTIL评分在调整临床病理变量和sTIL后未维持统计学显著预后关联,未显示增量预后价值。
  • 预后效能验证队列仅限早期三阴性乳腺癌,cTIL与sTIL相关分析队列为早期三阴性或HER2阳性乳腺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are a robust prognostic marker in patients with triple-negative breast cancer. Artificial intelligence (AI)-derived computational tools assessing TILs could improve efficiency, but require independent validation against clinical outcomes. We aimed to compare the prognostic performance of AI-derived TIL scores with pathologist-scored TILs in a large, prospectively collected dataset pooled from randomised controlled trials. METHODS: CATALINA was an independent, external validation study using prospectively collected long-term clinical outcome data pooled from seven randomised clinical trials conducted at multiple sites. We independently evaluated two previously validated AI pipelines that generate five computationally assessed tumour-infiltrating lymphocyte (cTIL) scores by masked, independent deployment of locked models. cTIL scores were correlated with the mean of the pathologist-scored stromal TILs (sTILs) in 220 digitised haematoxylin and eosin whole slide images in a cohort of patients with early-stage triple-negative or HER-2 positive breast cancer, previously scored by trained pathologists in a TIL-reproducibility study. Prognostic performance was assessed in a separate cohort of patients with early triple-negative breast cancer pooled from seven prospective, randomised adjuvant trials. Multivariable Cox regression models adjusted for clinicopathological factors and study heterogeneity assessed associations of cTIL score and sTIL score with invasive disease-free survival, distant disease-free survival, and overall survival. 5-year discrimination was estimated using time-dependent area under the receiver operating characteristic curve (AUC). FINDINGS: Individual data were collated from 1759 patients, of whom 1356 had complete clinicopathological data, pathologist sTIL scores, and cTIL scores available. Modest correlation (r 0·375-0·473) was observed between cTIL scores and the mean pathologist sTIL score. Both sTIL and cTIL were independently associated with 5-year invasive disease-free survival, distant disease-free survival, and overall survival after adjustment for clinicopathological factors (hazard ratio for invasive disease-free survival was 0·73 [95% CI 0·66-0·82]; q<0·0001, distant disease-free survival was 0·70 [0·61-0·79]; q<0·0001, and overall survival was 0·72 [0·63-0·82]; q<0·0001 for sTIL scores and 0·80 [0·73-0·89]; q<0·0001, 0·77 [0·69-0·86]; q<0·0001, and 0·79 [0·70-0·88]; q=0·0002, respectively, for percentage_lymphocyte scores). In models adjusted for clinicopathological variables and sTIL score, cTIL score did not maintain a statistically significant prognostic association. Both sTIL and cTIL scores improved the 5-year AUC over clinicopathological variables alone, while cTIL score did not significantly further improve AUC when combined with clinicopathological variables and sTIL score. INTERPRETATION: Two cTIL models deployed entirely without retraining or modification provided statistically significant prognostic information and improved risk discrimination compared with clinicopathological variables alone in this large, platform-based, independent validation study. Although cTIL score did not incrementally improve prognostication compared with models combining clinicopathological variables with sTIL score, these findings support the application of cTILs as a reproducible prognostic biomarker, particularly in settings where routine or widespread pathologist assessment is unavailable. FUNDING: Breast Cancer Research Foundation (USA).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Dixon-Douglas JR, Drubay D, Salgado R, et al. Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study. Lancet Oncol. 2026. PMID: 42636839. doi:10.1016/S1470-2045(26)00339-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。